Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alexion Pharmaceuticals (NQ: ALXN )

159.73 USD +1.87 (+1.18%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Alexion Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
ALEXION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. - ALXN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN)... 
From Business Wire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders About Its Ongoing Investigations
From PR Newswire
ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CHNG, OXFD, SMTX, OBLN, ALXN, BYFC, CIT
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 
From PR Newswire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 
From PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds MTSC, IPHI, ALXN and XLNX Shareholders About Its Ongoing Investigations
From PR Newswire
Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab) in Hospitalized Patients with Severe COVID-19 
From Business Wire News Releases
Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference
Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALXN, MGLN, FLIR, BEAT; Shareholders Are Encouraged to Contact the Firm
From GlobeNewswire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Reminds EIDX, IPHI, ALXN, and XLNX Shareholders About Its Ongoing Investigations
From PR Newswire
Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference
Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 
From PR Newswire
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages RP, MDCA, ALXN, SPWH Shareholders to Contact the Firm
From GlobeNewswire News Releases
WeissLaw LLP Reminds MTSC, EIDX, IPHI, and ALXN Shareholders About Its Ongoing Investigations
From PR Newswire
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers - ALXN, TCF, CATM, TCP
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 
From PR Newswire
Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm – PNM, ALXN, HMSY
From GlobeNewswire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Reminds TCF and ALXN Shareholders About Its Ongoing Investigations
From PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alexion Pharmaceuticals, Inc. - ALXN
From PR Newswire
ALEXION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. - ALXN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN)... 
From PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - ALXN, CATM, TCP, PRVL
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 
From PR Newswire
ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – ALXN, PS, HBAN, CKH
From GlobeNewswire News Releases
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Financialnewsmedia.com News Commentary 
From PR Newswire
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Alexion Pharmaceuticals, Inc. Buyout
From GlobeNewswire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) in... 
From PR Newswire
Thinking about buying stock in Pfizer, Moderna, Arvinas, Veru, or Alexion Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, ARVN, VERU, and ALXN. 
From PR Newswire
(ALXN): Johnson Fistel Investigates Proposed Sale of Alexion Pharmaceuticals; Are Shareholders Getting a Fair Deal?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) breached their... 
From PR Newswire
Alexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Alexion Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AL
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) to AstraZeneca PLC for $60.00 in cash and 2.1243 AstraZeneca... 
From Business Wire News Releases
AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development
AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development 
From Business Wire News Releases
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.